Takeda Pharmaceutical Co. v. Painters Fund


(U.S., filed March 27, 2020): Urging the Court to review whether the chain of causation between a manufacturer’s allegedly false statements and end payments for prescription drugs is too attenuated to satisfy RICO’s proximate cause requirement.  Also, to address whether everyone who pays for a product with an alleged latent risk or defect suffer injury sufficient to confer Article III standing.

Court denied cert

Latest News

View all news